PTPRB and diabetes mellitus: Recombinant Ang-1-, and Ang-2-blocking molecules, including inhibitors of VE-PTP, function in decreasing inflammation-associated vascular leakage and have therapeutic effects in diabetes, atherosclerosis, and ocular neovascular diseases.